In the OlympiAD study, the PARP inhibitor, olaparib, was compared with investigator’s choice chemotherapy (capecitabine, eribulin, or vinorelbine) in patients with metastatic HER2-negative breast cancer and germline BRCA1/2 pathogenic variants. Here, ERBB2 is linked to breast carcinoma.